Access in all areas? A round up of developments in market access and health technology assessment: part 2-Reference-Cited by-同舟云学术

Access in all areas? A round up of developments in market access and health technology assessment: part 2

Published:2023-12 Issue:12 Volume:12 Page:
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Beattie Alice¹,Treharne Catrin¹,Mardiguian Silvy²,Ramagopalan Sreeram V¹³

Affiliation:

1. Lane Clark & Peacock, London, W1U 1DQ, UK

2. BeiGene, London, EC4A 4AB, UK

3. Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK

Abstract

In this latest update, we explore the Inflation Reduction Act (IRA) enacted by the US Congress in August 2022, with the Centers for Medicare and Medicaid Services (CMS) recently releasing the list of the first ten drugs it will negotiate prices on. We also cover the consequences of price controls and rigid value assessment in Germany which have led to the withdrawal of a number of medicines. It will be important to see how the IRA balances cost-saving with holistic value assessment, incentives for innovation and patient access to treatment.

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://becarispublishing.com/doi/pdf/10.57264/cer-2023-0162

Reference20 articles.

1. Cubanski J Neuman T Freed M. Explaining the Prescription Drug Provisions in the Inflation Reduction Act (2023). www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/

2. New reforms to prescription drug pricing in the US: opportunities and challenges;Hwang TJ;JAMA,2022

3. Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 (2023). www.cms.gov/files/document/fact-sheet-medicare-selected-drug-negotiation-list-ipay-2026.pdf

4. Drugs likely subject to Medicare negotiation, 2026–2028;Dickson S;J. Manag. Care Spec. Pharm.,2023

5. ASPE. Inflation Reduction Act Research Series: Medicare Enrollees' Use and Out-of-Pocket Expenditures for Drugs Selected for Negotiation under the Medicare Drug Price Negotiation Program (2023). https://aspe.hhs.gov/reports/aspe-ira-drug-negotiation-fact-sheet